First Tracks Biotherapeutics, Inc. (TRAX) Balance Sheet

As of 2026-06-30 (10-Q), First Tracks Biotherapeutics, Inc. (TRAX) reported total assets of $183.1M and shareholders' equity of $168.8M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $168.0M.

Source: SEC EDGAR filings · read by EquiReason

TRAXFirst Tracks Biotherapeutics, Inc.Follow TRAX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.6B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 5 Nov, in 12 days

Balance-sheet dates are not available for this company yet.

USD millions · SEC XBRL

First Tracks Biotherapeutics, Inc. — questions

How much cash does First Tracks Biotherapeutics, Inc. have?: $168.0M in cash and cash equivalents as of 2026-06-30.
What are First Tracks Biotherapeutics, Inc.'s total assets?: $183.1M as of 2026-06-30.
What is First Tracks Biotherapeutics, Inc.'s shareholders' equity?: $168.8M as of 2026-06-30.

Every figure on this page comes from First Tracks Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.